Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Sahajanand Medical...

    Sahajanand Medical Technologies Announces enrolment of the First Patient in EverOCT Study in India

    Written by Ruby Khatun Khatun Published On 2017-06-13T11:12:11+05:30  |  Updated On 13 Jun 2017 11:12 AM IST
    Sahajanand Medical Technologies Announces enrolment of the First Patient in EverOCT Study in India

    Mumbai: SMT (Sahajanand Medical Technologies Pvt. Ltd.) India’s largest manufacturer of cardiovascular medical stents, has announced the enrolment of the first patient in EverOCT – Tetrilimus Optical Coherence Tomography (OCT) Study.


    EverOCT (Evaluation of the Tetrilimus EVERolimus-eluting Coronary Stent by Optical Coherence Tomography) study goal is to evaluate the malapposition, degree of strut coverage and vessel wall response after implantation of the biodegradable-polymer coated Tetrilimus Everolimus-eluting stent (EES) by OCT analysis. This would also be compared with the QCA analysis of the angiograms done at the time of OCT.


    The study is being conducted under the leadership of Dr Upendra Kaul who will be the principal investigator. He is a recipient of esteemed B. C. Roy award and was also conferred with the prestigious civilian award from the President of India. OCT analysis will be conducted at Cardiovascular Research Centre (CRC), under the direction of Alexandre Abizaid, MD, PhD, who is the Chairman of CRC and Director, Interventional Cardiology of Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil


    Commenting on the study, Mr Piyush Savalia Sr. V.P. Marketing & Clinical Trial, SMT said “Evidence Based Medicine is at the core of SMT’s product development strategy. We are committed to nurture the meaningful innovations that deliver better patient outcomes. Here we leverage a decade long healing experience while bringing the best of efficacy and safety outcomes offered through SMT DES, Tetrilimus, the 4th Generation stent system from SMT.”


    SMT is the pioneer to bring DES with biodegradable polymers. The trend set by SMT was followed by several players in the industry, owing to the clinical benefits of this innovative shift from the conventional durable polymers. In collaboration with leading cardiac interventionists, researchers worldwide, SMT offers the comprehensive range of innovative medical devices to address of cardiovascular treatment needs.


    About Tetrilimus:


    Ergonomically designed Tetrilimus (Everolimus Eluting Coronary Stent System) is unique in a way for its ultrathin conformal and proprietary biodegradable Polymeric coating (Polymer Matrix -PLLA, PLCL and PVP) which is designed to deliver the drug in a biphasic manner: an initial burst dose, followed by a controlled release of the drug which reduces late adverse clinical events.


    The strut thickness of Tetrilimus is 60µ which is lowest among all the predicate devices without compromising the radial strength. These features along with flexible Long Link connector; enhance vessel wall conformability, improve deliverability and extend the reach to more distal and tortuous lesions.


    Long term favourable clinical outcomes of SMT DES have been well supported by robust, ICH-GCP Compliant clinical trial program which has covered more than 12, 000 patients till date and its data has been published in various reputed indexed journals.

    B C Roy awardcardiovascular medical stentsCardiovascular Research CentreDr Alexandre AbizaidDr Upendra KaulEverOCTOptical Coherence Tomographypatient enrolmentSahajanand Medical TechnologiesSahajanand Medical Technologies Pvt. Ltd.SMTTetrilimusTetrilimus EVERolimus-eluting Coronary Stent
    Source : PRESS RELEASE

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok